AT-001

About Applied Therapeutics

Applied Therapeutics (Nasdaq: APLT) is a clinical-stage biotech founded in 2016 with a mission to develop transformative therapies for rare diseases by targeting well-validated molecular pathways. Its core achievement is the advancement of govorestat, a novel Aldose Reductase Inhibitor, into Phase 3 development for Classic Galactosemia and SORD Deficiency, utilizing biomarker-driven trial designs aligned with new FDA guidance. The company's strategic focus on regulatory acceleration and validated biology is poised for a significant inflection point, bolstered by a pending acquisition by Cycle Pharmaceuticals Group which aims to provide the capital and operational expertise needed to bring these critical therapies to market.

Therapeutic Areas